Coagulation factor XII, Human, mAb 10-11-37
Monoclonal antibody 10-11-37 recognizes Coagulation Factor XII (FXII, Hageman factor). FXII is a
serine protease and plays a role in blood coagulation, fibrinolysis, kinin and complement systems. The
protein is the zymogen of the serine protease factor XIIa (FXIIa). FXII is converted to FXIIa through
autoactivation induced by contact to charged surfaces, also known as the plasma contact system. FXII
is predominantly synthesized in the liver and is composed of fibronectin type I and II domains, two
epidermal growth factor-like domains, a kringle region, a proline-rich domain and a catalytic domain. Its
molecular weight is approximately 80kDa on SDS-PAGE gel electroforeses. The protein circulates in
the plasma at a concentration of 30-35 μg/ml.
FXII forms the plasma contact system together with high molecular weight kininogen and plasma
kalikrein. FXII autoactivates when these three proteins form a complex on negatively charged
nonphysiological surfaces, like inorganic surfaces (eg silicon tubes) or macromolecular organic surfaces
(eg heparin) bound to the surface of different cell types, including endothelial cells, platelets and
neutrophils. It can trigger blood coagulation and generation of proinflammatory bradykinin. After surface
complexation, FXII autoactivates into FXIIa, also called factor XII fragment(XIIf). Once small amounts
of kalikrein are formed a positive feedback loop is active leading to enhanced conversion into FXIIa.
The activation leads to a series of active enzyme formation. FXIIa converts prekallikrein to kallikrein and
kallikrein digests kinogen to liberate proinflammatory bradykinin. Bradykinin triggers inflammatory
reactions via activating endothelial cells resulting in vasodilatation, increased vascular permeability and
production of other mediators like nitric oxide.
The contact system has the ability to activate the complement system via the classical pathway.
Simultaneous activation of both systems may lead to pathological conditions, like hereditary
angioedema in individuals with dysfunctional C1-inhibitor (C1-IHB). FXIIa can activate complement
protein C1r and to a lesser degree C1s in absence of C1-IHB. This leads to unimpeded bradykinin
formation resulting in angioedema. Other interactions with complement system are found on the level
of gC1qR and MASP-1. The antibody is specific for the heavy chain of FXIIa.
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA